News

Physicians typically do not overestimate the overall health of people with ANCA-associated vasculitis (AAV), a study of global assessments made by patients and their doctors in Australia reports. In cases where ratings between these two groups markedly differed, doctors tended to assign a lower score than did the people…

Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV), showed a favorable safety profile in a Phase 2 clinical trial, the company has announced. A separate study testing lixudebart in people with liver disease also showed a good safety…

Adicet Bio has pushed to the second half of 2025 the expected timing for enrolling patients with ANCA-associated vasculitis (AAV) in an ongoing Phase 1 clinical trial testing ADI-001, an experimental CAR T-cell therapy for a number of autoimmune diseases. The company had said it expected enrollment…

Most children with ANCA-associated vasculitis (AAV) and kidney involvement at diagnosis will exhibit inactive kidney disease after one year, and more than two in five will show evidence of permanent kidney damage, according to data from an international registry study. A glomerular filtration rate (eGFR) — a standard measure…

More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses, often in the respiratory tract, with more than one-third developing severe infections. That’s according to a meta-analysis of published data, which also identified several risk factors for infections in this…

A reduced glucocorticoid dosing regimen for inducing disease remission in people with ANCA-associated vasculitis (AAV) may be associated with a higher risk of poor disease outcomes in those with severe disease, compared with the standard-dose regimen. That’s according to a real-world study in France and Luxembourg that involved people…

Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy candidate in people with ANCA-associated vasculitis (AAV). The trial had been expected to begin in 2025. While details on that planned Phase 2 trial in AAV patients had…

Enrollment is now open for a small clinical trial designed to test dose-escalating doses of experimental cell therapy NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. Called Ntrust-2, the study will assess the therapy’s safety and ability to promote long-term disease remissions in an initial group…

Eosinophilic granulomatosis with polyangiitis (EGPA) should be considered in people with uncontrolled severe asthma and high blood levels of immune cells called eosinophils — a hallmark of the autoimmune disease — according to the findings of a study from Singapore. This rare type of ANCA-associated vasculitis (AAV) was…

Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults with ANCA-associated vasculitis (AAV) at higher risk of developing severe infections, a study in the U.S. suggests. Being age 75 or older, but not frail, was linked to a…